One more bispecific, humanized IgG1 antibody that may be underneath investigation is zenocutuzumab (MCLA-128), which acts by means of two impartial mechanisms of action: inhibition of HER2–HER3 signalling and elimination of tumour cells by way of ADCC. MCLA-128 functions through a ‘dock and block’ system whereby 1 arm with the https://www.directivepublications.org/journal-of-clinical-breast-cancer/